GLP-1 Drugs and Kidney Function: What T2D Patients With CKD Need to Know

The relationship between GLP-1 drugs and kidney function has shifted substantially with the FLOW trial results. What was previously a question of "safe to use in CKD?" has become "can these drugs actually protect the kidney?"

This article awaits medical-reviewer signoff.

Background: CKD in the T2D population

Type 2 diabetes is the leading cause of chronic kidney disease (CKD) and end-stage renal disease in the United States. Approximately 40% of T2D patients develop diabetic kidney disease over their lifetime. CKD progression in T2D is driven by:

• Chronic hyperglycaemia damaging glomerular capillaries
• Systemic hypertension transmitted to the glomerulus
• Inflammation and oxidative stress
• Intra-glomerular hypertension (a renin-angiotensin-aldosterone system [RAAS] effect)

Before the GLP-1 era, the only drugs with demonstrated kidney-protective effects beyond glucose control were RAAS blockers (ACE inhibitors, ARBs) and, more recently, SGLT2 inhibitors.

The FLOW trial

Published in the New England Journal of Medicine in 2024, FLOW (Semaglutide in Patients with Chronic Kidney Disease and Type 2 Diabetes) was a double-blind RCT of semaglutide 1 mg weekly versus placebo in 3,533 T2D patients with:

• eGFR 24–89 ml/min/1.73 m² (CKD stages 2–4)
• UACR ≥100 mg/g (elevated albuminuria)

The primary endpoint was a composite: sustained 50%+ eGFR decline, kidney failure, death from kidney disease, or death from cardiovascular disease.

The trial was stopped early for efficacy. At the pre-specified interim analysis, semaglutide had reduced the primary composite by 24% (hazard ratio 0.76, 95% CI 0.66–0.88). The number needed to treat was approximately 20 patients over the study period to prevent one primary endpoint event.

Secondary endpoints also favoured semaglutide:

• eGFR slope (rate of kidney function decline): slower in semaglutide group
• Albuminuria: reduced in semaglutide group
• Cardiovascular events: reduced

Regulatory consequence: The FDA approved an updated Ozempic (semaglutide 1 mg) label in 2024 adding an indication for kidney disease risk reduction in T2D patients with CKD.

Mechanisms of kidney protection

The kidney-protective effects of GLP-1 therapy likely involve multiple pathways:

Glucose lowering: Improved glycaemic control reduces the direct toxic effects of hyperglycaemia on glomerular cells.

Blood pressure reduction: GLP-1 therapy produces modest blood pressure reductions (2–5 mmHg systolic on average), reducing transmission of systemic hypertension to glomerular capillaries.

Weight loss: Adipose tissue-driven inflammation and obesity-related glomerulopathy are reduced.

Anti-inflammatory and anti-oxidative effects: Direct GLP-1 receptor signalling in the kidney is proposed to reduce inflammatory cytokine production and oxidative stress in tubular and mesangial cells.

RAAS effects: GLP-1 agonism may modulate intra-renal RAAS activity, reducing intra-glomerular pressure.

Dosing in CKD: no adjustment typically needed

GLP-1 receptor agonists are primarily eliminated via enzymatic degradation (peptidase activity), not via the kidney. Renal elimination is a minor pathway. Therefore:

• Dose adjustment for kidney function (eGFR) is not typically required for semaglutide, tirzepatide, or liraglutide
• Patients with CKD stages 2–4 can generally receive standard doses
• Severe CKD (eGFR below 15, i.e. stage 5/ESRD) or dialysis: limited data; clinical judgment and prescriber guidance required

The GI side effect caveat: Patients with CKD have reduced physiological reserve to compensate for dehydration. GLP-1 GI side effects (nausea, vomiting, diarrhoea) can cause significant fluid losses. In a patient with CKD, dehydration-related acute kidney injury is a more serious concern than in a patient with normal kidney function.

Practical implication: patients with CKD starting GLP-1 therapy should be specifically counselled on hydration maintenance during periods of nausea or vomiting, and should have lower threshold for contacting their prescriber if GI side effects are significant.

Tirzepatide and kidney outcomes

Tirzepatide's kidney outcomes data is emerging. SURPASS-CVOT includes kidney endpoints. Preliminary data suggests favourable kidney trends consistent with the GLP-1 class and its dual GIP mechanism. An equivalent dedicated kidney trial to FLOW for tirzepatide had not yet reported as of May 2026.

Implications for clinical practice

For T2D patients with CKD, the FLOW data adds kidney disease risk reduction to the existing reasons to consider semaglutide alongside RAAS blockade and SGLT2 inhibitors. The combination of RAAS blocker + SGLT2 inhibitor + GLP-1 agonist represents a multi-pathway approach to slowing diabetic kidney disease progression that is increasingly discussed in nephrology.

Discuss the kidney-protection data and its relevance to your specific CKD stage and trajectory with your prescriber or nephrologist.

Editorial note: This article awaits medical-reviewer signoff. CKD management requires individualised clinical assessment. Do not adjust your medications without consulting your prescriber or nephrologist.